Spots Global Cancer Trial Database for Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Official Title: A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group, Exploratory Phase 2 Study to Assess Efficacy and Safety of Selexipag in Adult Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis
Study ID: NCT02260557
Study Description
Brief Summary: The primary objective of the study is to determine the activity of selexipag on Raynaud attack frequency in subjects with Raynaud's Phenomenon (RP) secondary to Systemic Sclerosis (SSc).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Investigator Site, Grenoble cedex, , France
Investigator Site, Lille Cedex, , France
Investigator Site, Nantes Cedex 1, , France
Investigator Site, Paris, , France
Investigator Site, Strasbourg, , France
Investigator Site, Bad Nauheim, , Germany
Investigator Site, Berlin, , Germany
Investigator Site, Erlangen, , Germany
Investigator Site, Koln, , Germany
Investigator Site, Magdeburg, , Germany
Investigator Site, Mainz, , Germany
Investigator Site, Bath, , United Kingdom
Investigator Site, Leeds, , United Kingdom
Investigator Site, Liverpool, , United Kingdom
Investigator Site, London, , United Kingdom
Investigator Site, Salford, , United Kingdom
Contact Details
Name: Ralph Preiss, MD
Affiliation: Actelion
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
